S. 476 · 116th Congress
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
WydenSponsor5 cosponsors · 5 D
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
What it does: CRS summary · Introduced in Senate · Feb 13, 2019
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
This bill establishes a series of requirements relating to drug rebates and discounts under Medicare and Medicare Advantage (MA).
Specifically, for each pharmacy benefits manager (PBM) that contracts with a prescription drug plan (PDP) under Medicare or MA, or with a qualified health benefits plan offered through a health insurance exchange, HHS must publish on its website (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies.
As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan.
The bill also modifies requirements regarding Medicare enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Latest action (Feb 13, 2019): Read twice and referred to the Committee on Finance.
Policy area: Health · Origin: Senate · Introduced: Feb 13, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.